Department of Hepatology and Gastroenterology, Ghent University Hospital, Ghent, Belgium.
Hepatol Res. 2013 Sep;43(9):991-8. doi: 10.1111/hepr.12043. Epub 2013 May 15.
Fanconi anemia (FA) is an inherited bone marrow failure syndrome due to defective DNA inter-strand cross-link repair. Hematopoietic stem cell transplantation (HSCT) is curative for pancytopenia, but may not prevent the development of non-hematological malignancies. We describe a 26-year-old male patient with FA and Marfan syndrome who in 1994 underwent successful HSCT with bone marrow stem cells from his human leukocyte antigen (HLA)-identical sister. In 2006, three lesions in the liver were detected and resected. The three lesions all showed activation of the β-catenin pathway and were histologically characterized by a highly differentiated steatotic hepatocellular carcinoma (HCC) with remnants of the underlying adenoma from which it arose, a hepatocellular adenoma with foci of well-differentiated HCC, and a cholestatic adenoma. Risk factors for the emergence of HCC included FA itself, the use of androgens for a period of 3 years preceding HSCT and toxicity of the conditioning regimen. Because of the danger of developing additional HCC, liver transplantation was proposed, taking into consideration that immunosuppression would increase the risk of other malignancies. By using part of the liver of the sister, who already acted as bone marrow donor 13 years earlier, immunosuppression could be avoided. Liver transplantation was performed in 2007 without complication. Five years after liver transplantation the patient is doing well. This case is twofold special being the first case reporting FA co-occurring with Marfan syndrome and being the first reported case of FA treated for HCC by liver transplantation from a HLA-identical sibling donor without the use of immunosuppression.
范可尼贫血(FA)是一种遗传性骨髓衰竭综合征,由于 DNA 链间交联修复缺陷所致。造血干细胞移植(HSCT)可治愈全血细胞减少症,但可能无法预防非血液系统恶性肿瘤的发生。我们描述了一位 26 岁男性 FA 合并马凡综合征患者,1994 年他接受了来自 HLA 完全相同的姐姐的骨髓干细胞 HSCT,手术成功。2006 年,患者肝脏发现三个病灶并进行了切除。三个病灶均显示β-catenin 通路激活,组织学表现为高度分化的伴有脂肪变性的肝细胞癌(HCC),伴有起源于其下腺瘤的残余物,一个具有分化良好 HCC 灶的肝细胞腺瘤,和一个胆汁淤积性腺瘤。HCC 出现的危险因素包括 FA 本身、HSCT 前 3 年使用雄激素以及预处理方案的毒性。由于存在发生其他 HCC 的危险,建议进行肝移植,考虑到免疫抑制会增加发生其他恶性肿瘤的风险。由于使用了 13 年前已经作为骨髓供者的姐姐的一部分肝脏,可以避免免疫抑制。2007 年进行了肝移植,无并发症。肝移植后 5 年,患者情况良好。该病例有两个特殊之处,一是首次报道 FA 合并马凡综合征,二是首例 FA 患者通过 HLA 完全相同的同胞供体进行肝移植治疗 HCC,而无需使用免疫抑制。